Domestic development biosimilar and botulinum toxin drugs expand their influence in the U.S
Hanmi Pharmaceutical's neutropenia treatment Rolvedon has succeeded in entering the U.S. market. Starting with LG Chem's Factual in 2003, a total of six new drugs made with domestic technology passed the U.S. licensing gate.

However, it is evaluated that new domestic development drugs that have entered the U.S. so far have a long way to go to achieve commercial success. Although it is not a new drug, biosimilars and botulinum toxin drugs developed with domestic technologies are gradually expanding their market impact and writing a success story.

◆Hanmi Pharmaceutical's bio-new drug FDA's fi